Yes-associated protein-1 may serve as a diagnostic marker and therapeutic target for residual/recurrent hepatocellular carcinoma post-transarterial chemoembolization
Background and aim: The transcriptional co-activator Yes-associated protein-1 (YAP1) has been implicated as an oncogene and is overexpressed in different kinds of human cancers, especially hepatocellular carcinoma (HCC). However, the role of YAP1 has not been reported in residual/recurrent HCC after...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
KeAi Communications Co., Ltd.
2020-12-01
|
Series: | Liver Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2542568420300581 |
id |
doaj-64e3011785474e5bbbb120914e176e48 |
---|---|
record_format |
Article |
spelling |
doaj-64e3011785474e5bbbb120914e176e482021-04-02T17:50:19ZengKeAi Communications Co., Ltd.Liver Research2542-56842020-12-0144212217Yes-associated protein-1 may serve as a diagnostic marker and therapeutic target for residual/recurrent hepatocellular carcinoma post-transarterial chemoembolization Xia Qian0Wei Zhang1Alireza Shams2Kahee Mohammed3Alex S. Befeler4Ningling Kang5Jinping Lai6Department of Pathology, Saint Louis University School of Medicine, Saint Louis, MO, USADivision of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Florida, Gainesville, FL, USA; Corresponding author. Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Florida, Gainesville, FL, USA.Department of Pathology, Saint Louis University School of Medicine, Saint Louis, MO, USADepartment of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, MO, USADivision of Gastroenterology and Hepatology, Saint Louis University School of Medicine, Saint Louis, MO, USAThe Hormel Institute, University of Minnesota and Mayo Clinic, Austin, MN, USADepartment of Pathology, Saint Louis University School of Medicine, Saint Louis, MO, USA; Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL, USA; Department of Pathology and Laboratory Medicine, Kaiser Permanente Sacramento Medical Center, Sacramento, CA, USA; Corresponding author. Department of Pathology and Laboratory Medicine, Kaiser Permanente Sacramento Medical Center, Sacramento, CA, USA.Background and aim: The transcriptional co-activator Yes-associated protein-1 (YAP1) has been implicated as an oncogene and is overexpressed in different kinds of human cancers, especially hepatocellular carcinoma (HCC). However, the role of YAP1 has not been reported in residual/recurrent HCC after transarterial chemoembolization (TACE). Our aim is to determine whether YAP1 is overexpressed in the residual/recurrent HCC after TACE. Methods: A total of 105 tumor tissues from 71 patients including 30 cases of primary HCC without prior treatment, 35 cases of residual/recurrent HCC post TACE, and 6 cases of hepatoblastoma were included in the immunohistochemical study. YAP1 immunoreactivity was blindly scored as 0, 1+, 2+ or 3+ in density and percentages of positive cells. Results: About 33.3% (10/30) of primary HCC without prior treatment showed 2+ of YAP1 immunoreactivity. While 82.8% (29/35) of residual/recurrent HCCs after TACE treatment displayed 2–3+ of YAP1 immunoreactivity, which was significantly higher compared to primary HCC without prior treatment (P = 0.0002). YAP1 immunoreactivity was moderately to strongly positive (2–3+) in 100% of the hepatoblastoma, particularly in the embryonal components (3+ in 100% cases). Conclusions: YAP1 is significantly upregulated in the residual/recurrent HCCs post TACE treatment, suggesting that YAP1 may serve as a sensitive diagnostic marker and a treatment target for residual/recurrent HCC post TACE.http://www.sciencedirect.com/science/article/pii/S2542568420300581Yes-associated protein-1 (YAP1)Residual/recurrent hepatocellular carcinomaHepatoblastomaCancer stem cell (CSC)ImmunohistochemistryTransarterial chemoembolization (TACE) |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xia Qian Wei Zhang Alireza Shams Kahee Mohammed Alex S. Befeler Ningling Kang Jinping Lai |
spellingShingle |
Xia Qian Wei Zhang Alireza Shams Kahee Mohammed Alex S. Befeler Ningling Kang Jinping Lai Yes-associated protein-1 may serve as a diagnostic marker and therapeutic target for residual/recurrent hepatocellular carcinoma post-transarterial chemoembolization Liver Research Yes-associated protein-1 (YAP1) Residual/recurrent hepatocellular carcinoma Hepatoblastoma Cancer stem cell (CSC) Immunohistochemistry Transarterial chemoembolization (TACE) |
author_facet |
Xia Qian Wei Zhang Alireza Shams Kahee Mohammed Alex S. Befeler Ningling Kang Jinping Lai |
author_sort |
Xia Qian |
title |
Yes-associated protein-1 may serve as a diagnostic marker and therapeutic target for residual/recurrent hepatocellular carcinoma post-transarterial chemoembolization |
title_short |
Yes-associated protein-1 may serve as a diagnostic marker and therapeutic target for residual/recurrent hepatocellular carcinoma post-transarterial chemoembolization |
title_full |
Yes-associated protein-1 may serve as a diagnostic marker and therapeutic target for residual/recurrent hepatocellular carcinoma post-transarterial chemoembolization |
title_fullStr |
Yes-associated protein-1 may serve as a diagnostic marker and therapeutic target for residual/recurrent hepatocellular carcinoma post-transarterial chemoembolization |
title_full_unstemmed |
Yes-associated protein-1 may serve as a diagnostic marker and therapeutic target for residual/recurrent hepatocellular carcinoma post-transarterial chemoembolization |
title_sort |
yes-associated protein-1 may serve as a diagnostic marker and therapeutic target for residual/recurrent hepatocellular carcinoma post-transarterial chemoembolization |
publisher |
KeAi Communications Co., Ltd. |
series |
Liver Research |
issn |
2542-5684 |
publishDate |
2020-12-01 |
description |
Background and aim: The transcriptional co-activator Yes-associated protein-1 (YAP1) has been implicated as an oncogene and is overexpressed in different kinds of human cancers, especially hepatocellular carcinoma (HCC). However, the role of YAP1 has not been reported in residual/recurrent HCC after transarterial chemoembolization (TACE). Our aim is to determine whether YAP1 is overexpressed in the residual/recurrent HCC after TACE. Methods: A total of 105 tumor tissues from 71 patients including 30 cases of primary HCC without prior treatment, 35 cases of residual/recurrent HCC post TACE, and 6 cases of hepatoblastoma were included in the immunohistochemical study. YAP1 immunoreactivity was blindly scored as 0, 1+, 2+ or 3+ in density and percentages of positive cells. Results: About 33.3% (10/30) of primary HCC without prior treatment showed 2+ of YAP1 immunoreactivity. While 82.8% (29/35) of residual/recurrent HCCs after TACE treatment displayed 2–3+ of YAP1 immunoreactivity, which was significantly higher compared to primary HCC without prior treatment (P = 0.0002). YAP1 immunoreactivity was moderately to strongly positive (2–3+) in 100% of the hepatoblastoma, particularly in the embryonal components (3+ in 100% cases). Conclusions: YAP1 is significantly upregulated in the residual/recurrent HCCs post TACE treatment, suggesting that YAP1 may serve as a sensitive diagnostic marker and a treatment target for residual/recurrent HCC post TACE. |
topic |
Yes-associated protein-1 (YAP1) Residual/recurrent hepatocellular carcinoma Hepatoblastoma Cancer stem cell (CSC) Immunohistochemistry Transarterial chemoembolization (TACE) |
url |
http://www.sciencedirect.com/science/article/pii/S2542568420300581 |
work_keys_str_mv |
AT xiaqian yesassociatedprotein1mayserveasadiagnosticmarkerandtherapeutictargetforresidualrecurrenthepatocellularcarcinomaposttransarterialchemoembolization AT weizhang yesassociatedprotein1mayserveasadiagnosticmarkerandtherapeutictargetforresidualrecurrenthepatocellularcarcinomaposttransarterialchemoembolization AT alirezashams yesassociatedprotein1mayserveasadiagnosticmarkerandtherapeutictargetforresidualrecurrenthepatocellularcarcinomaposttransarterialchemoembolization AT kaheemohammed yesassociatedprotein1mayserveasadiagnosticmarkerandtherapeutictargetforresidualrecurrenthepatocellularcarcinomaposttransarterialchemoembolization AT alexsbefeler yesassociatedprotein1mayserveasadiagnosticmarkerandtherapeutictargetforresidualrecurrenthepatocellularcarcinomaposttransarterialchemoembolization AT ninglingkang yesassociatedprotein1mayserveasadiagnosticmarkerandtherapeutictargetforresidualrecurrenthepatocellularcarcinomaposttransarterialchemoembolization AT jinpinglai yesassociatedprotein1mayserveasadiagnosticmarkerandtherapeutictargetforresidualrecurrenthepatocellularcarcinomaposttransarterialchemoembolization |
_version_ |
1721553227713871872 |